AR024292A1 - INHIBIDORES DE FACTOR VIIA, UN PROCESO PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA Y USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO PARA REDUCIR LA COAGULACIoN EN SANGRE O RESPUESTA INFLAMATORIA DESoRDENES CARDIOVASCULARES, ENFERMEDADES TROMBOEMBOLíTICAS O RESTENOSIS. - Google Patents

INHIBIDORES DE FACTOR VIIA, UN PROCESO PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA Y USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO PARA REDUCIR LA COAGULACIoN EN SANGRE O RESPUESTA INFLAMATORIA DESoRDENES CARDIOVASCULARES, ENFERMEDADES TROMBOEMBOLíTICAS O RESTENOSIS.

Info

Publication number
AR024292A1
AR024292A1 ARP000102796A ARP000102796A AR024292A1 AR 024292 A1 AR024292 A1 AR 024292A1 AR P000102796 A ARP000102796 A AR P000102796A AR P000102796 A ARP000102796 A AR P000102796A AR 024292 A1 AR024292 A1 AR 024292A1
Authority
AR
Argentina
Prior art keywords
blood
preparation
compounds
cardiovastic
bulbescules
Prior art date
Application number
ARP000102796A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR024292A1 publication Critical patent/AR024292A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente se refiere a compuestos de la Formula (1) en la cual R1, R2, R91, R92, R93, R94, R95, R96, R97, r, s y t tienen los significados indicados enlas reivindicaciones. Los compuestos de la Formula (1) son valiosos compuestosfarmacologicamente activos. Ellos exhiben un fuerte efecto antitrombotico y sonadecuados, por ejemplo, para la terapia y la profilaxis de enfermedades tromboembolíticas o restenosis. Son inhibidores reversibles de la enzima de coagulacionde lasangre factor VIIa y pue den aplicarse en general en condiciones en las cuales se presenta una actividad no deseada del factor VIIa o para la cura oprevencion de los casos en los que se pretende una inhibicion del factor VIIa. La presente además serefiere a procesos para la preparacion de compuestos deFormula (1), a su uso, en particular como ingredientes activos en composiciones farmacéuticas, y a las preparaciones farmacéuticas que los comprenden.
ARP000102796A 1999-06-08 2000-06-06 INHIBIDORES DE FACTOR VIIA, UN PROCESO PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA Y USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO PARA REDUCIR LA COAGULACIoN EN SANGRE O RESPUESTA INFLAMATORIA DESoRDENES CARDIOVASCULARES, ENFERMEDADES TROMBOEMBOLíTICAS O RESTENOSIS. AR024292A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111109A EP1059302A1 (en) 1999-06-08 1999-06-08 Factor VIIa inhibitors

Publications (1)

Publication Number Publication Date
AR024292A1 true AR024292A1 (es) 2002-09-25

Family

ID=8238315

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102796A AR024292A1 (es) 1999-06-08 2000-06-06 INHIBIDORES DE FACTOR VIIA, UN PROCESO PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA Y USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO PARA REDUCIR LA COAGULACIoN EN SANGRE O RESPUESTA INFLAMATORIA DESoRDENES CARDIOVASCULARES, ENFERMEDADES TROMBOEMBOLíTICAS O RESTENOSIS.

Country Status (32)

Country Link
US (1) US6500803B1 (es)
EP (2) EP1059302A1 (es)
JP (1) JP4546683B2 (es)
KR (1) KR100979069B1 (es)
CN (1) CN1359390B (es)
AR (1) AR024292A1 (es)
AT (1) ATE246707T1 (es)
AU (1) AU774037B2 (es)
BR (1) BR0011461A (es)
CA (1) CA2376064C (es)
CZ (1) CZ300365B6 (es)
DE (1) DE60004363T2 (es)
DK (1) DK1189929T3 (es)
EE (1) EE04855B1 (es)
ES (1) ES2202137T3 (es)
HK (1) HK1047289B (es)
HR (1) HRP20010912B1 (es)
HU (1) HUP0201451A3 (es)
IL (2) IL146731A0 (es)
ME (1) MEP57708A (es)
MX (1) MXPA01012568A (es)
NO (1) NO328249B1 (es)
NZ (1) NZ515966A (es)
PL (1) PL202879B1 (es)
PT (1) PT1189929E (es)
RS (1) RS50415B (es)
RU (1) RU2248359C2 (es)
SI (1) SI1189929T1 (es)
SK (1) SK286902B6 (es)
TR (1) TR200103550T2 (es)
WO (1) WO2000075172A2 (es)
ZA (1) ZA200110053B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
DE10005631A1 (de) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
WO2002062829A1 (fr) * 2001-02-02 2002-08-15 Chugai Seiyaku Kabushiki Kaisha Derives de peptide
GB0127615D0 (en) * 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
ATE455103T1 (de) * 2005-06-24 2010-01-15 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2007131996A1 (en) * 2006-05-12 2007-11-22 Genmedica Therapeutics Sl Meta-xylylenediamine vanadate salts
WO2017210489A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. Compounds
WO2021001458A1 (en) 2019-07-01 2021-01-07 Tonix Pharma Holdings Limited Anti-cd154 antibodies and uses thereof
CA3207098A1 (en) 2021-01-06 2022-07-14 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
CA2186497C (en) * 1994-04-26 2008-06-17 Fahad Al-Obeidi Factor xa inhibitors
DE69717268T2 (de) * 1996-02-22 2003-09-04 Bristol-Myers Squibb Pharma Co., Wilmington M-amidinophenyl-analoga als faktor-xa-inhibitoren
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors

Also Published As

Publication number Publication date
SK17592001A3 (sk) 2002-05-09
NO20016005L (no) 2002-02-06
TR200103550T2 (tr) 2002-05-21
HK1047289A1 (en) 2003-02-14
NO20016005D0 (no) 2001-12-07
MEP57708A (en) 2011-05-10
ATE246707T1 (de) 2003-08-15
EE04855B1 (et) 2007-06-15
ES2202137T3 (es) 2004-04-01
HRP20010912B1 (en) 2010-10-31
EP1189929B1 (en) 2003-08-06
PL202879B1 (pl) 2009-07-31
CA2376064A1 (en) 2000-12-14
EP1189929A2 (en) 2002-03-27
SI1189929T1 (en) 2004-02-29
JP4546683B2 (ja) 2010-09-15
SK286902B6 (sk) 2009-07-06
HRP20010912A2 (en) 2003-04-30
WO2000075172A3 (en) 2001-05-31
AU5397600A (en) 2000-12-28
CN1359390A (zh) 2002-07-17
NO328249B1 (no) 2010-01-18
YU86101A (sh) 2004-07-15
MXPA01012568A (es) 2002-04-10
KR100979069B1 (ko) 2010-08-31
PL352200A1 (en) 2003-08-11
EP1059302A1 (en) 2000-12-13
DE60004363D1 (de) 2003-09-11
RU2248359C2 (ru) 2005-03-20
IL146731A0 (en) 2002-07-25
PT1189929E (pt) 2003-12-31
HUP0201451A2 (en) 2002-08-28
AU774037B2 (en) 2004-06-17
RS50415B (sr) 2009-12-31
CA2376064C (en) 2011-04-26
WO2000075172A2 (en) 2000-12-14
NZ515966A (en) 2003-09-26
DK1189929T3 (da) 2003-11-24
CZ20014357A3 (cs) 2002-03-13
KR20020020728A (ko) 2002-03-15
US6500803B1 (en) 2002-12-31
ZA200110053B (en) 2002-07-03
HUP0201451A3 (en) 2003-08-28
CN1359390B (zh) 2010-05-26
BR0011461A (pt) 2002-03-19
HK1047289B (zh) 2010-10-22
CZ300365B6 (cs) 2009-04-29
DE60004363T2 (de) 2004-06-24
EE200100662A (et) 2003-04-15
IL146731A (en) 2007-07-24
JP2003502294A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
UY28778A1 (es) Derivados de pirrol como inhibidores del factor xa
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
AR024292A1 (es) INHIBIDORES DE FACTOR VIIA, UN PROCESO PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA Y USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO PARA REDUCIR LA COAGULACIoN EN SANGRE O RESPUESTA INFLAMATORIA DESoRDENES CARDIOVASCULARES, ENFERMEDADES TROMBOEMBOLíTICAS O RESTENOSIS.
YU48416B (sh) Novi derivati hidroksamske kiseline i n-hidroksikarbamida i postupci za njihovo dobijanje
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
PT1227820E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BR0312232A (pt) Inibidores de caspases e seus usos
CA2141056C (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
ATE399002T1 (de) Pharmazeutische zubereitungen für die behandlung von läsionen der haut und schleimhäute und diese verwendende verfahren und kits
HUP0100558A2 (hu) S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
HUP0400553A2 (hu) Gyógyászati készítmények
AR026257A1 (es) N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
ECSP056178A (es) Derivados de bencimidazol como inhibidores del factor xa
US6488912B1 (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
ECSP056179A (es) Derivados de azaindol como inhibidores del factor xa
TR200103144T2 (tr) Yeni bileşikler
NO328979B1 (no) Anvendelse av diklorbenzylalkohol for fremstilling av et preparat for topisk behandling av inflammasjon
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
Khokhlenkova Prospects of using biopolymeric films in medicine and pharmacy

Legal Events

Date Code Title Description
FG Grant, registration